Threshold Pharmaceuticals Announces Presentation and Webcast at the Oppenheimer 24th Annual Healthcare Conference
December 03 2013 - 7:00AM
Marketwired
Threshold Pharmaceuticals Announces Presentation and Webcast at the
Oppenheimer 24th Annual Healthcare Conference
SOUTH SAN FRANCISCO, CA--(Marketwired - Dec 3, 2013) - Threshold
Pharmaceuticals, Inc. (NASDAQ: THLD) today announced that Barry
Selick, Ph.D., Threshold's Chief Executive Officer, will present a
company overview at the Oppenheimer 24th Annual Healthcare
Conference on December 10, 2013, at 2:10 p.m. ET.
A live webcast of the presentation will be available under
Webcasts in the Investors section of www.thresholdpharm.com. A
replay of the presentation will be archived on the site for 30
days.
About Threshold Pharmaceuticals Threshold Pharmaceuticals, Inc.
is a biotechnology company focused on the discovery and development
of drugs targeting tumor hypoxia, the low oxygen condition found in
the microenvironments of most solid tumors as well as the bone
marrows of some patients with hematologic malignancies. This
approach offers broad potential to treat a variety of cancers. By
selectively targeting tumor cells, we are building a pipeline of
drugs that hold promise to be more effective and less toxic to
healthy tissues than conventional anticancer drugs. For additional
information, please visit our website (www.thresholdpharm.com).
Forward-Looking Statements Except for statements of historical
fact, the statements in this press release are forward-looking
statements, including statements regarding the potential
therapeutic uses and benefits of its product candidates. These
statements involve risks and uncertainties that can cause actual
results to differ materially from those in such forward-looking
statements. Potential risks and uncertainties include, but are not
limited to, Threshold's ability to enroll or complete its
anticipated clinical trials, the time and expense required to
conduct such clinical trials and analyze data, issues arising in
the regulatory or manufacturing process and the results of such
clinical trials (including product safety issues and efficacy
results). Further information regarding these and other risks is
included under the heading "Risk Factors" in Threshold's Quarterly
Report on Form 10-Q, which has been filed with the Securities and
Exchange Commission on November 4, 2013 and is available from the
SEC's website (www.sec.gov) and on our website
(www.thresholdpharm.com) under the heading "Investors." We
undertake no duty to update any forward-looking statement made in
this news release.
Contact Laura Hansen, Ph.D. Senior Director, Corporate
Communications Threshold Pharmaceuticals Phone: 650-474-8206
E-mail: lhansen@thresholdpharm.com
Molecular Templates (NASDAQ:MTEM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Molecular Templates (NASDAQ:MTEM)
Historical Stock Chart
From Apr 2023 to Apr 2024